News Article

ANP's NIDS® COVID-19 Antigen Rapid Test Kit Successfully Detects Omicron Variant
Date: Jan 04, 2022

Source: Company Data ( click here to go to the source)

Featured firm in this article: ANP Technologies Inc of Newark, DE

Newark, DE (Jan. 4, 2022) -- ANP Technologies Inc. (ANP), announced that its NIDS® COVID-19 Antigen Rapid Test Kit has successfully detected the SARS-CoV-2 Omicron variant from nasal samples. The detection has been further confirmed with an FDA EUA approved RT-PCR, followed by sequencing analysis.

"This is a significant validation and confirmation of ANP's Antigen rapid test for the detection of the latest COVID-19 variant, Omicron. Our preliminary data indicate that the NIDS® COVID-19 Antigen Rapid Test has similar sensitivity for the Omicron variant as compared to the original SARS-CoV-2 virus." Said Dr. Ray Yin, President and CTO of ANP. "While some of the rapid antigen tests currently on the market showed reduced sensitivity towards the Omicron variant, our nanotechnology enhanced assay platform allows us to maintain high sensitivity for the detection of the Omicron variant providing a great tool for early detection and isolation of those who get infected with this latest version of the virus."

The NIDS® COVID-19 Antigen Rapid Test Kit is authorized for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in mid-turbinate (MT) nasal swabs from individuals who are suspected of having COVID-19 by their healthcare provider within the first seven (7) days of symptom onset or from individuals without symptoms or other epidemiological reasons to suspect COVID-19 when tested twice over two or three days with at least 24 hours and no more than 36 hours between tests.

​About ANP Technologies, Inc.
ANP Technologies, Inc. is a clinical stage biopharmaceutical company and a world leader in developing innovative nano-therapeutics and nano-diagnostic tests. ANP has been a premier provider to supply its rapid multiplexed lateral flow tests for the detection of various biological agents to the Department of Defense in the past 15 years, as well as successfully licensed various pre-clinical and clinical stage nanotherapeutics to companies such as Celgene/BMS and Fulgent Pharma. Visit anptinc.com and anpcovid.com for more information.

###
CONTACT:
Greg Witham, MS
302-283-1730
Greg.Witham@anptinc.com